17LBA Results from an open-label, randomized, controlled Phase 3 study investigating IMA901 multipeptide cancer vaccine in patients receiving sunitinib as first-line therapy for advanced/metastatic RCC

Rini, Brian I.; Stenzl, A.; Zdrojowy, Romuald; Kogan, M.I.; Школьник, М. И.; Оудард, С.; Weikert, Steffen; Bracarda, Sergio; Crabb, Simon J.; Bedke, Jens; Ludwig, Joerg; Maurer, Dominik; Mendrzyk, Regina; Mahr, Alfred; Fritsche, Jens; Weinschenk, Toni; Singh, Harwinder; Kirner, Alexandra; Reinhardt, Carsten; Eisen, Tim

doi:10.1016/s0959-8049(16)31939-6

Cited by 22 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Various recent phase III therapeutic cancer vaccine trials (Magrit, telomerase vaccine GV1001, Stimuvax, Immatics, etc.) failed to achieve their primary objectives (3,4). Improvement of cancer vaccine design is therefore mandatory for their clinical implementation.…”

mentioning

confidence: 99%

Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines

Nizard

Roussel

Tartour

2016

Clinical Cancer Research

View full text Add to dashboard Cite

Cancer vaccine boost via the cervicovaginal rather than the intramuscular route of immunization appears to be crucial to induce genital CD8+ T cells and tumor regression. This clinical activity is correlated with the ability of the mucosal boost to elicit resident memory T cells in the genital tract. Clin Cancer Res; 22(3); 530–2. ©2015 AACR. See related article by Sun et al., p. 657

show abstract

mentioning

confidence: 99%

Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines

Nizard

Roussel

Tartour

2016

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…In separate research of phase 3 involving 339 patients, the efficiency of combination therapy with sunitinib, IMA-901 and GM-CSF was assessed. Addition of IMA-901 to sunitinib did not show any effects (Rini et al 2015).…”

Section: Kidney Cancer Cell Therapymentioning

confidence: 86%

Renal cell carcinoma drug and cell therapy: today and tomorrow

Pushkin¹,

Burda²,

Sevast’yanov³

et al. 2018

RRP

View full text Add to dashboard Cite

Today, considerable progress in the renal cell carcinoma (RCC) treatment has been made due to development of targeted and immunotherapeutic approaches to the RCC treatment, especially in metastasising carcinoma. In the early stages of RCC, it is possible to use partial or total surgical nephrectomy, but in metastases development, the range of efficient treatment methods is dramatically limited. Appearance of targeted drugs like PD-1 and CTLA-4 receptors and their ligands' inhibitors in clinical practice has significantly increased the total survival rate of patients with renal cell carcinoma. Emergence of adoptive cell therapy has opened new possibilities and prospects in RCC treatment. Previously activated in vitro cells are used there, which provides antineoplastic activity. For example, it could be antigen-specific cytotoxic T-lymphocytes (CTL), lymphokine-activated natural killers (LAK-NK-cells) and tumour-infiltrating lymphocytes (TILs). In this review, the authors specified the main molecular markers, associated with RCC; and signalling pathways (VEGFR-and EGFR-signalling pathway), which directly take part in carcinogenesis. The paper also looks at clinically applicable targeted immune drugs and the principle of their effect on tumorous cells. Besides, modern clinical studies of cell drugs have been considered. At the moment, there are a number of variants of targeted and immune drugs for the metastatic RCC treatment. Patients have no opportunity to use all the available agents because of their cost and toxicity level. For the most efficient treatment of patients with diagnosed metastatic RCC, it is necessarily to carry out risk stratification and prognostic factors for the response to treatment.

show abstract

“…Vogl Tumor vaccines have also not shown any improvement in either the metastatic setting or in the adjuvant treatment (31).…”

Section: Discussionmentioning

confidence: 99%